TOBI // EU Project

Project description:

The TOBI project aims to analyse mechanisms, which provoke adipokine-mediated crosstalk and an inflammatory drift in obese patients. It will be the remit of this project to develop novel strategies to reduce or reverse major adipokine-mediated adverse interactions in peripheral tissues and by periorganic adipose tissue, namely insulin resistance and vascular dysfunction, respectively. Special attention will be given to the study of novel lipid-derived adipokines and the identification of targets for drug development that could interfere with the obesity-associated inflammatory drift. TOBI research focuses on molecular mechanisms, which initiate and promote inflammatory signalling pathways in adipocytes and adipose tissue macrophages that cause a shift to inflammatory adipokines, which interfere with insulin sensitivity and vascular function. Adipocyte dysfunction caused by alterations in ER stress signalling and lipolysis will be analysed as a probable starting point for adipocyte inflammatory alterations. Signalling pathways and transcription factors controlling expression of inflammatory adipokines and anti-inflammatory adipokines will be studied. TOBI will in particular investigate lipid-derived adipokines that have been little studied to date. Key molecules of pathophysiological relevance will be validated for their potential as targets for drug development. The TOBI consortium will mount a comprehensive collaborative program for analysing the molecular mechanisms underlying regulation of adipokine production and their function in target tissues using genetic, molecular and biochemical approaches. The consortium combines all necessary expertise to investigate the basis of the obesity-associated inflammatory drift. A TOBI toolbox will be developed that strengthens collaboration and comparability of results. In addition the consortium includes suitable partners to exploit the results by translating them into new treatment strategies for obesity-associated adipokine-mediated disorders.

biolution contribution:

Partners / Collaborations

biolution GmbH, AT
Medical University of Vienna, AT
Pharm-Analyt Labor GmbH, AT
University of Graz, AT
Genfit SA, FR
Pasteur Institute of Lille, FR
University of Köln, DE
Marche Polytechnic University, IT
University of Durham, UK
The University of Edinburgh, UK

Related items:

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.